Cuiyun Li
Overview
Explore the profile of Cuiyun Li including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
87
Citations
480
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Feng B, Li C, Zhang Z, Huang Y, Liu B, Zhang Z, et al.
J Nanobiotechnology
. 2025 Feb;
23(1):110.
PMID: 39955548
The continuously evolving Omicron subvariants has diminished the effectiveness of almost all RBD-targeted antibodies in neutralizing these subvariants. The development of broad-spectrum neutralizing antibodies is desired for addressing both current...
2.
Li C, Mai J, Wu M, Zhang H, Li X, Li H, et al.
Antimicrob Agents Chemother
. 2024 Dec;
69(2):e0137724.
PMID: 39688408
This study evaluated the safety and pharmacokinetics (PK) of a single dose of leritrelvir, a novel inhibitor of 3-chymotrypsin-like cysteine protease (3CLpro), in patients with hepatic impairment versus healthy participants...
3.
Li X, Xu J, Sun J, Liu J, Wu M, Zhang H, et al.
Liver Int
. 2024 Dec;
45(1):e16213.
PMID: 39673713
Background And Aims: Freethiadine is a novel hepatitis B virus capsid assembly modulator. Herein, we report the safety, tolerability, pharmacokinetics and 28-day antiviral activities of freethiadine. Methods: The study consisted...
4.
Li X, Li B, Yang D, Wang M, Li Q, Wang N, et al.
JAMA Dermatol
. 2024 Dec;
PMID: 39661362
Importance: Psoriasis is a chronic, immune-mediated skin disease with an unmet need for biologic treatment options. Objective: To assess the safety, pharmacokinetics, and efficacy of QX004N in healthy individuals and...
5.
Zhang H, Li Q, Li C, Wu M, Chen H, Li Y, et al.
Lancet Rheumatol
. 2024 Oct;
6(12):e837-e847.
PMID: 39454617
Background: Proximod is a selective agonist of sphingosine-1-phosphate receptor-1 (S1PR1). It acts by redirecting lymphocytes from the circulation to secondary lymph nodes, and is under development as an immunomodulator for...
6.
Li C, Li H, Mai J, Zhang H, Wu M, Ding Y, et al.
J Clin Pharmacol
. 2024 Sep;
65(2):226-232.
PMID: 39287964
This study compared the safety and pharmacokinetics of a single oral dose of onradivir, an inhibitor of polymerase basic protein 2 in influenza A virus, in patients with hepatic impairment...
7.
Zhang X, Li C, Liu M, Sun J, Yue H, Bao H
Appl Nurs Res
. 2024 Mar;
75:151763.
PMID: 38490794
Background: Previous studies have identified the antecedents of the lifestyle of many patients with chronic diseases. However, the mechanism of social support affecting the lifestyle of patients with chronic diseases...
8.
Huang S, Wen X, Liu Z, Li C, He Y, Liang J, et al.
Front Psychiatry
. 2024 Jan;
14:1343195.
PMID: 38169701
Background: This study aims to investigate the underlying characteristics of spontaneous brain activity by analyzing the volumes of the hippocampus and parahippocampal gyrus, as well as the fractional amplitude of...
9.
Xu J, Chen H, Zhu X, Jia H, Xu Z, Huo D, et al.
Ann Med
. 2023 Dec;
55(2):2264850.
PMID: 38071661
TQA3526 is a novel farnesoid X receptor agonist developed to treat non-alcoholic steatohepatitis (NASH) or primary biliary cholangitis (PBC). This study aimed to evaluate the safety, tolerability, pharmacokinetics (PK), and...
10.
Li C, Wu M, Zhang H, Zhu X, Fu L, Wang S, et al.
Ann Med
. 2023 Nov;
55(2):2274512.
PMID: 37980573
Background: Forsythin, an active compound from Forsythiae Fructus, has the potential to treat the common cold and influenza through its antipyretic-analgesic, anti-inflammatory and antiviral effects. The safety, tolerability and pharmacokinetic...